Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

59.63 +0.89 (+1.52%)
Official Closing Price Updated: 7:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,362,903
Open 59.00
Bid (Size) 59.71 (1)
Ask (Size) 59.89 (1)
Prev. Close 58.74
Today's Range 58.45 - 60.09
52wk Range 45.05 - 120.56
Shares Outstanding N/A
Dividend Yield 3.69%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk (NVO) Soars as HSBC Upgrades to "Buy," Citing Strategic Focus and Pipeline Strength
Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC.... 
Via MarketMinute
Topics Economy
This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga

Performance

YTD
-31.9%
-31.9%
1 Month
+5.1%
+5.1%
3 Month
-14.0%
-14.0%
6 Month
-4.7%
-4.7%
1 Year
-48.2%
-48.2%

More News

Read More
Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors
Via Chartmill
Why Shares in Novo Nordisk Bumped Higher Today
Via The Motley Fool
Topics Government World Trade
Novo Nordisk Retail Traders Stay Bullish Despite Brutal 2025 — Analysts Flag A Key Catalyst That Can Turn Things Around
Via Stocktwits
LifeMD Offers Novo Nordisk’s Ozempic For $499 A Month To Eligible Patients
Via Stocktwits
Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today
Via Stocktwits
Q3 2025 Market Marvels: S&P 500's Standout Performers and Their Catalysts
Via MarketMinute
Topics Artificial Intelligence Data Breach Earnings
Pfizer Plummets as Key Obesity Drug Candidate Faces Major Setback, Shaking Investor Confidence
Via MarketMinute
Topics Intellectual Property
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi, LLP
Via Business Wire
Trump's Plan To Lower U.S. Drug Prices Faces Big Test
Via Investor's Business Daily
Topics Government
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
Why Is Novo Nordisk Stock Down in 2025, and Is It a Buying Opportunity?
Via The Motley Fool
These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Why Novo Nordisk Stock Slumped on Monday
Via The Motley Fool
Topics World Trade
Deadline Soon: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
NOVO URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via TheNewswire.com
Topics Fraud Lawsuit
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Via NewMediaWire
Topics Fraud Lawsuit
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
3 Magnificent Stocks Under $100 to Buy Right Now
Via The Motley Fool
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 59.63
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 10/03/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.